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ABSTRACT
Objective: To characterize dropouts from type-2 diabetes (T2D) care in communal primary health
care.
Design: An observational study.
Setting: In a Finnish city, patients with T2D who had not contacted the public primary health
care system during the past 12 months were identified with a computer based search and con-
tacted by a trained diabetes nurse.
Subjects: Dropouts from T2D treatment.
Main outcome measures: Demographic factors, laboratory parameters, examinations, medica-
tions, and comorbidities.
Results: Of the patients with T2D, 10% (n¼ 356) were dropouts and 60% of them were men.
Median HbA1c was 6.5 (QR for 25% and 75%: 6.0, 7.7) %, (45 [42,61] mmol/mol). Of the dropouts,
14% had HbA1c 9.0% (75mmol/mol), and these patients were younger than the other dropouts
(mean age 54.4 [SD 10.8] years vs. 60.6 [9.4] years, p< 0.001). Median low-density lipoprotein
(LDL) cholesterol level was 2.8 (QR 2.1, 3.4) mmol/l. Median systolic blood pressure (BP) was 142
(QR 130, 160) mm Hg. Median diastolic BP was 86 (78, 94) mm Hg. Of the dropouts, 83% had
comorbidities and 62% were prescribed metformin as a treatment.
Conclusions: Ten percent of T2D patients were dropouts of whom those with a poor glycaemic
control were younger than the other dropouts. BP and LDL cholesterol concentrations were non-
optimal among the majority of the dropouts. Metformin was prescribed less frequently to the
dropouts than is usual for T2D patients. The comorbidities were equally common among the
dropouts as among the other T2D patients.
KEY POINTS
Which kinds of patients are dropouts from type-2 diabetes care is not known.
 One-tenth of the patients with T2D were dropouts and they generally had good
glycaemic control.
 Blood pressure and LDL cholesterol concentrations were non-optimal among the majority
of the dropouts.
 Fourteen percent of these dropouts had HbA1c > 9% (75mmol/mol) and they were more
often younger than the other dropouts.
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Introduction
In Finland, primary health care is mainly funded
through taxation, while public health care is a non-
profit system. Consequently, most patients with type-2
diabetes (T2D) are treated within the public health
care system by their general practitioners (GPs). For
the public health care system, treating T2D and espe-
cially diabetic complications is expensive.[1,2] As a
complementary profit-driven system, there is a private
health care system, which is, however, rather expensive
to use for private persons. Private patients with T2D
using private health care are in a minority and they
cover the expenses by private money or by insurances.
As an exception to this rule, there are those patients
whose occupational health is organized via the private
sector. In these cases, the employers are responsible
for the costs.
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It is a well-known fact that some of the diabetic
patients do not attend their regular controls.
Underlying reasons for withdrawing from diabetes
health care are numerous including working status, dis-
tance to the clinic, and type of diabetes manage-
ment.[3–5] However, data and information on
explanatory factors are inconsistent.[4] In previous
studies, the dropout rates vary widely from one per-
cent to 57%.[4,5] Unfortunately, these estimates of
dropout rates come, with two exceptions, from differ-
ent intervention studies and this variation is mainly
explained by factors like different study populations,
interventions, sample size, and study design.[4] A
German study concerning both primary and secondary
care T2D patients describes a dropout rate of 5.5%
during two years of follow-up from normal clinical
treatment, for example, a local T2D disease manage-
ment program.[5] In a purely primary care-driven treat-
ment system, the dropout rate was 6.3%, but it varied
between 2.8% and 10.8% depending on the ethnic ori-
gin of the T2D patients.[6] Neither of these studies
gives a lot of information about factors concerning
demographics, laboratory parameters, examinations,
medication, and comorbidities of these patients.
Furthermore, knowledge of what kind of individuals
compose this group of dropouts is vague and does
not provide a comprehensive picture. As far as we
know, there are no studies where such factors as qual-
ity of treatment, demographic factors or medications
are systemically described.
Theoretically, these dropouts should be brought
back to the health care system in order to prevent dia-
betic complications and to improve diabetes care. To
get these dropouts back into health care, they should
first be identified and brought back within the system.
Whether re-contacting and recruiting would be worth-
while is unknown.
In the City of Vantaa, Finland, the public health
authorities started an intervention to reach the drop-
outs with T2D in the public primary health care. The
aim of this study was to characterize these dropouts.
Here, we present the demographic data and character-
istics of the dropout patients with T2D.
Research design and methods
Setting
This retrospective observational cohort study was per-
formed in the public primary health care of the eastern
districts of the City of Vantaa. At the time of the study,
Vantaa had a population of 195,397 inhabitants, and in
the eastern districts, there were 118,802 inhabitants. Of
the inhabitants, 49% were males.
Data extraction
In the eastern districts of Vantaa, we identified all
patients aged 18–80 years who had an ICD-10 code
containing an E11 code in the patient charts or who
were prescribed specific hyperglycaemic drugs for T2D
from 1 January 2005 to 31 December 2009. A com-
puter-based search was made from Finstar (Logica,
Helsinki, Finland) patient chart system with a specific
report generator.
Patients who fulfilled the described T2D criteria but
had not contacted the public health care system dur-
ing the past 12 months (year 2009) were entered into
the data base. To detect whether these patients were
true dropouts or whether they were receiving alterna-
tive treatment (e.g., having the treatment arranged in
another system, private, or secondary care), the nurses
of the public health care system contacted them by
phone. A trained diabetes nurse contacted all these
putative dropouts in order to improve their diabetes
treatment and to bring them back within the public
primary diabetes care system.
The investigators ‘‘per se’’ did not contact the drop-
outs. We recorded the effects of the work performed
by the community primary health care nurses and GPs.
Ethical permission for the study was granted by the
Ethical committee of the Hospital District of Helsinki
and Uusimaa and health authority of the Vantaa City.
Primary and secondary outcomes
We recorded the dropouts’ gender, marital status,
immigration status, and occupation from the patient
charts. The dropouts were grouped into social classes
according to a classification originally described by
Statistics Finland (http://www.stat.fi/meta/luokitukset/
ammatti/001-2010/index.html). We also recorded drop-
outs’ height, weight, duration of diabetes, HbA1c, blood
pressure (BP), blood lipids (cholesterol, low-density
lipoprotein [LDL] cholesterol, high-density lipoprotein
[HDL] cholesterol, triglycerides), haemoglobin, alanine
transaminase, creatinine, prevalence of proteinuria and
retinopathy, and described use of hyperglycaemic
drugs from patient charts. Recorded comorbidities with
International Classification of Diseases 10 (ICD-10) diag-
noses were collected and reported in main diagnostic
groups.
The dropouts were divided into three groups
based on their HbA1c (< 7.0% [53mmol/mol] 7.0%
[53mmol/mol] to 9.0% [75mmol/mol], and >9.0%
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[75mmol/mol]) for further assessments of the level of
diabetes care. A similar division was previously used in
a Finnish nationwide report on the quality of diabetes
care.[7,8] The dropouts were assessed to have protein-
uria, if the level of albuminuria was 20 lg/min or more.
Some patient charts had insufficient data, and there-
fore, we do not have complete data on all parameters
studied.
Statistics
Data were expressed as means and standard devia-
tions (SD) or medians and quartile ranges (QR for 25%
and 75%) depending on the test used. Comparisons of
frequencies were performed with v2 test. Comparisons
between the sexes were performed by using Student’s
t-test or Mann–Whitney U-test when appropriate. Two-
way analysis of variance (ANOVA) was used to analyse
the effects of the quality of the diabetes care as deter-
mined by the studied parameters. Statistical analyses
were carried out using SigmaPlot 10.0 (Systat Software
INC, San Jose, CA).
Results
Demographics
In the eastern districts of Vantaa, 3459 people fulfilled
the criteria of having T2D. Of those, 10% (n¼ 356)
were dropouts from the public primary health care. Of
the contacted dropouts, 83% came to the laboratory
tests prescribed by a trained diabetes nurse. The rest
did not come because they were unwilling to partici-
pate, had their diabetes care arranged elsewhere in
the private sector, or did not respond to any contact
efforts. The majority of the dropouts (60%) were men.
Table 1 shows the demographics of the dropouts.
Most (91%) of the dropouts were cohabiting. Living
alone was more frequent among women than among
men (p< 0.05). Men were more frequently highly edu-
cated (management and professionals) or blue collar
workers, and women white collar workers. Only three
of the dropouts were characterized as immigrants.
Mean age of the dropouts was 59.4 (9.9) years and
no statistically significant differences were observed
between men and women. Mean duration of T2D was
6.3 (4.6) years. Table 2 shows the characteristics of the
dropouts. Women were statistically significantly more
obese than men (p< 0.01).
Laboratory parameters and examinations
Table 3 shows the results of the laboratory tests,
examinations of the eye fundus and BP among the
dropouts. Median HbA1c was 6.5 (QR 6.0, 7.7) %, for
example, 48 (QR 42, 61) mmol/mol. Median LDL chol-
esterol was 2.8 (QR 2.1, 3.4) mmol/l; women had a
higher concentration than men (p< 0.01). Mean sys-
tolic BP was 147 (23) mmHg and median was 142 (QR
130, 160) mmHg. Mean diastolic BP was 87 (12) mmHg
and median was 86 (78, 94) mmHg. No BP differences
were observed between men and women. Men had
proteinuria more often than women (24% vs. 12%,
p< 0.05). There was no statistically significant differ-
ence in the prevalence of retinopathy between men
and women.
Medications
Table 4 shows hyperglycaemic drugs prescribed to the
dropouts. Of the dropouts, 62% were prescribed met-
formin as a treatment for T2D and the mean daily
Table 1. Demographic data of the dropouts (N¼ 356).
Males, n (%) Females, n (%)
Sex 214 (60.1%) 142 (39.9%)
Married and cohabiting 116 (94.3%) 64 (84.2%)
Single, widows and divorced 7 (5.6%) 12 (15.8%)
Social group (according to Finnish Statistics, based on occupation)
class 1 highly educated (management and professionals) 28 (13.1%) 6 (4.2%)**
class 2 white collar workers (experts, office workers and clerks) 58 (27.1%) 62 (43.7%)***
class 3 blue collar workers (service, sales, construction, repair, manufacturing, process and transport workers) 82 (38.3%) 35 (24.6%)**
class 4 othersa 46 (21.5%) 39 (27.5%)
**p 0.01,
***p< 0.001, v2 test
a31 persons (10.7%) were retired, but we found former occupations of 13 of these persons. These persons are placed into the social group respecting their
former occupation.
Table 2. Characteristics of the dropouts.
Males (214) Females (142)
mean SD mean SD
Age, y 59.8 9.1 58.8 10.9
Weight, kg 96.6 20.5 87.6*** 20.1
Height, cm 175.9 6.3 162.1*** 6.7
Body mass index, kg/m2 30.8 6.4 33.2** 7.1
Duration of diabetes, y 6.6 4.9 5.9 4.1
males versus females
**p< 0.01,
***p< 0.001, t-test
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dose was 1986 (839) milligrams. Insulin was prescribed
to 12% of dropouts. Mean daily doses for long-acting
insulin analogues were 71 (56) international units (IU),
for NPH-insulins 93 (141) IU and for rapid-acting insu-
lins 38 (29) IU. Glitazones were prescribed more often
to men than to women.
Comorbidities
A majority of the dropouts (83%) had comorbidities.
The number of comorbidities varied greatly: 17% had
none, 24% one, 22% two, and 37% had three or more.
Women had more comorbidities (2.5 [2.0]) than men
(2.0 [1.7], p< 0.05). The most common comorbidities
were cardiovascular disease (67%), primarily hyperten-
sion. Other endocrinopathies than diabetes (39%), pri-
marily dyslipidaemia, were also common. The
prevalence of comorbidities among the dropouts is
presented in Figure 1.
Quality of T2D treatment
Figure 2 shows the distribution of dropouts in different
HbA1c groups. Of the dropouts, 14% had HbA1c 9.0%
(75mmol/mol); they were younger than the other
dropouts (mean age 54.4 [10.8] years vs. 60.6 [9.4]
years, p< 0.001) and they were more often prescribed
insulin than the other dropouts (33% vs. 10%,
p< 0.001), but no differences were observed in sex,
duration of diabetes, BMI, number of comorbidities or
social class.
Discussion
Among public primary health care patients with T2D,
about 10% were dropouts and the majority of them
were men. The glycaemic control among dropouts
reflected well the general level of glycaemic control
among T2D patients (median 6.7% [50mmol/mol]) in
Finland at the time of the study quite closely.[8]
Table 3. Findings of the laboratory tests, examinations of the eye fundus, and blood pressure among
the dropouts.
Males (214) Females (142)
HbA1c, % (mmol/mol) 6.3 (5.7, 7.4) (48 [42, 59]) 6,3 (5.8, 7.4) (46 [41, 63])
Cholesterol, mmol/l 4.7 (3.9, 5.4) 5.0** (4.1, 5.9)
LDL Cholesterol, mmol/l 2.7 (2.0, 3.3) 3.0** (2.3, 3.7)
HDL Cholesterol, mmol/l 1.2 (1, 1.4) 1,3** (1.1, 1.5)
Triglycerides, mmol/l 1.6 (1.1, 2.3) 1.7 (1.3, 2.3)
Haemoglobin, g/l 148.0 (139.0, 156.0) 141.0*** (131.3, 149.0)
Alanine transaminase, U/l 32.0 (20.3, 49.6) 29.0 (18.0, 46.0)
Creatinine, lmol/l 74 (64, 85) 59*** (50, 66)
Systolic blood pressure (mm Hg)a 145.1 (20.8) 147.1 (24.5)
Diastolic blood pressure (mm Hg)a 86.3 (11.5) 86.8 (12.3)
Retinopathyb 27.0 (34) 28.4 (21)
Results are presented as median (QR for 25% and 75%) unless otherwise stated as
amean (SD),
b% (n)
Males versus females
**p< 0.01,
***p< 0.001, Mann–Whitney U-test
Table 4. Prescriptions of hyperglycaemia drugs among the
dropouts.
Males
(n¼ 214)
Females
(n¼ 142)
Metformin, % (n) 62.6 (134) 62.0 (88)
Detemir or glargine insulins, % (n) 7.5 (16) 4.9 (47)
NPH-insulins, % (n) 4.7 (10) 5.6 (8)
Mixed insulins (rapid and slow acting), % (n) 0.5 (1) 0
Rapid insulins, % (n) 1.9 (4) 2.8 (4)
Glitazones, % (n) 9.8 (21) 2.1 (3)**
DPP4-inhibitors, % (n) 2.8 (6) 2.1 (3)
Sulphonylureas or glinides, % (n) 20.1 (43) 15.5 (22)
Males versus females
**p< 0.01, v2 test.
DPP4: dipeptidyl peptidase 4.
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However, levels of diastolic BP and LDL cholesterol
were on average higher than among Finnish patients
with T2D. At the time of the study median, BP level
was 142/81mmHg and median LDL cholesterol level
2.4mmol/l in Finnish T2D.[8] Metformin was prescribed
to over 60% of the dropouts.
According to our study findings, the dropout rate
among public primary health care patients with T2D
was 10%, which was almost twice as high as in a previ-
ous community-based study from Germany [5] and
60% higher than the mean dropout rate reported from
New Zealand.[6] Furthermore, 17% of the dropouts did
not return to the communal diabetes care system after
the contact of a trained diabetes nurse. We found that
a majority of dropouts were men, which is in line with
most previous observations.[5,9] Our study findings
showed that over 60% of dropouts had well-controlled
glucose levels, being similar to the general level of gly-
caemic control in Finnish patients with T2D at the time
of the study.[8] On the other hand, almost 15% of
dropouts had poor glycaemic control, which is more
than commonly observed among Finnish patients with
T2D.[7,8] The dropouts with poorly controlled gly-
caemia were significantly younger than the other drop-
outs. Insulin was prescribed to these dropouts three
times as often as to the other dropouts. Furthermore,
according to our study findings, the public primary
care dropouts, both men and women, had non-optimal
levels of diastolic BP and LDL cholesterol. Previous
study findings in relation to HbA1c, BP, and lipids are
partially inconsistent, which may be explained by dif-
ferent study designs.[4,5,9] Yet, presently observed sex
differences, for example, higher total,[10] LDL- [10–13]
and HDL cholesterol [10] concentrations, and BMI
[11,12] in women, and higher incidence of proteinuria
in men,[14] have been reported in different non-drop-
out T2D patient populations by others as well.
Metformin was prescribed to over 60% of the drop-
outs in the present study, being the most commonly
used hyperglycaemic drug among them. Current
guidelines for diabetes recommend metformin as first-
line therapy unless contraindicated.[2] Generally, in
Finland, at the time of the study, metformin was pre-
scribed to almost 90% of the patients with T2D.[15]
Insulin was prescribed to about 12% of the dropouts,
which is about half of the general rate of insulin pre-
scriptions among Finnish patients with T2D at the time
of the study.[10] In the year 2009, incretin-based drugs
were rarely used in Finland. Previous study findings in
relation to the correlation between a dropout with a
T2D diagnosis and the type of diabetes medication
being used are inconsistent.[4,5]
According to our study findings, most of the T2D
dropouts in the public primary health care had some
comorbidities. Typically, patients with T2D have comor-
bidities and it has been shown that half of the patients
have three or more chronic comorbidities.[16] In our
study, the most common comorbidities among the
dropouts were hypertension and dyslipidaemia.
Findings in previous studies have shown that about
75% of the patients with T2D have hypertension and/
or dyslipidaemia.[16–18] The previous studies concern-
ing diabetic dropouts have reported inconsistent
results in relation to comorbidities.[4]
Because diabetes is one of the most important dis-
eases globally increasing the risk for disability,[19] it is
important for primary health care to find and identify
T2D dropouts and to try to optimize the treatment. At
present, the guidelines for T2D treatment emphasize a
holistic care and individually tailored treatment targets
for the patient with the disease.[2] With an optimal
treatment strategy, including treatment of glycaemia,
BP, lipids, and lifestyle factors, it is possible to reduce
the risk of both micro- and macrovascular
complications.[20]
There are some limitations to our study.
Unfortunately, we did not have data on dropouts’ life-
style factors, including sedentary behaviour or physical
activity, dietary or sleeping patterns, and smoking and
alcohol consumption. Further, we did not have infor-
mation on the underlying reasons for withdrawing
from diabetes care. Data on other medication than dia-
betes medication were not available. All study partici-
pants except three were of European ancestry. We did
not have a possibility to form a control group of non-
dropouts in the present study. Above all, those
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dropouts who should have had their T2D treatment in
the private sector or in occupational health care set-
ting were missing. Furthermore, if a T2D dropout was
originally diagnosed and totally treated outside the
public health care system, for example, he received no
diabetes care from health centres, we would have no
information on this kind of person. Therefore, the pre-
sent data do not reflect all primary care T2D dropouts.
These factors may have an influence on the results
and this should be kept in mind when interpreting the
study findings.
Conclusions
Overall, we report a dropout rate of 10% among T2D
patients and the majority of them were men. Most of
the dropouts in the public primary health care had a
good glycaemic control but 14% had HbA1c level
9.0% (75mmol/mol). The poorly controlled dropouts
were typically younger than the other dropouts. The
levels of BP and LDL cholesterol were non-optimal
among the majority of the dropouts. Only 60% of the
dropouts were prescribed metformin. The comorbid-
ities were common and similar to those typically seen
in T2D patients.
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